Mizoribine attenuates renal injury and macrophage infiltration in patients with severe lupus nephritis

Clinical Rheumatology

Volumn 29, Issue 9, 2010, Pages 1049-1054

  Tanaka, Hiroshi ^a   Oki, Eishin ^a   Tsuruga, Kazushi ^a   Aizawa Yashiro, Tomomi ^a   Ito, Yuya ^a   Sato, Norihiro ^c   Kawasaki, Yukihiko ^b   Suzuki, Junzo ^b  

^a HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c Laboratory for Safety Assessment   (Japan)

Author keywords

Chronicity indices; Diffuse proliferative lupus nephritis; Histologic progression; Macrophage infiltration; Mizoribine

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHYLPREDNISOLONE; MIZORIBINE; OSTEOPONTIN; PREDNISOLONE;

ADOLESCENT; AMENORRHEA; ARTICLE; CELL INFILTRATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION; HUMAN; HUMAN TISSUE; HYPERURICEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY BIOPSY; KIDNEY INJURY; LEUKOPENIA; LIVER DYSFUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROPHAGE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD;

ADOLESCENT; BIOPSY; CELL MOVEMENT; CHILD; ENZYME INHIBITORS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LUPUS NEPHRITIS; MACROPHAGES; MALE; RENAL INSUFFICIENCY; RIBONUCLEOSIDES; SEVERITY OF ILLNESS INDEX;

EID: 77956188711     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-010-1484-5     Document Type: Article

References (14)

1. S Yokota 2002 Mizoribine: mode of action and effects in clinical use Pediatr Int 44 196 198 10.1046/j.1328-8067.2002.01536.x 1:CAS:528: DC%2BD38XjtlCisbw%3D 11896886
2. H Tanaka E Oki K Tsuruga N Sato H Matsukura A Matsunaga Y Kondo J Suzuki 2008 Mizoribine treatment of young patients with severe lupus nephritis: a clinicopathologic study by the Tohoku Pediatric Study Group Nephron Clin Pract 110 c73 c79 10.1159/000151721 1:CAS:528:DC%2BD1cXhsVGhtLnL 18758186
3. Y Kawasaki M Hosoya J Suzuki N Onishi A Takahashi M Isome R Nozawa H Suzuki 2004 Efficacy of multidrug therapy combined with mizoribine in children with diffuse IgA nephropathy in comparison with multidrug therapy without mizoribine and with methyprednisolone pulse therapy Am J Nephrol 24 576 581 10.1159/000082202 1:CAS:528:DC%2BD2MXnvVCgtA%3D%3D 15550753
4. Y Ikezumi T Suzuki T Karasawa H Kawachi DJ Nikolic-Paterson M Uchiyama 2008 Use of mizoribine as a rescue drug for steroid-resistant pediatric IgA nephropathy Pediatr Nephrol 23 645 650 10.1007/s00467-007-0664-2 18038158
5. H Tanaka K Tsugawa E Oki K Suzuki S Waga E Ito 2007 Long-term mizoribine intermittent pulse therapy, but not azathioprine therapy, attenuated histologic progression in a patient with severe lupus nephritis Clin Nephrol 68 198 200 1:STN:280:DC%2BD2srpsVKgtw%3D%3D 17915627 (letter)
6. N Sato K Shiraiwa K Kai A Watanabe S Ogawa Y Kobayashi H Yamagishi-Imai Y Utsunomiya T Mitarai 2001 Mizoribine ameliorates the tubulointerstitial fibrosis of obstructive nephropathy Nephron 89 177 185 10.1159/000046065 1:CAS:528:DC%2BD3MXntlemtrw%3D 11549900
7. Y Kikuchi T Imakiire M Yamada T Saigusa T Hyodo N Hyodo S Suzuki S Miura 2005 Mizoribine reduces renal injury and macrophage infiltration in non-insulin-dependent diabetic rats Nephrol Dial Transplant 20 1573 1581 10.1093/ndt/gfh888 1:CAS:528:DC%2BD2MXmsV2htL8%3D 15905195
8. S Takahashi Y Taniguchi A Nakashima T Arakawa T Kawai S Doi T Ito T Masaki N Kohno N Yorioka 2009 Mizoribine suppresses the progression of experimental peritoneal fibrosis in a rat model Nephron Exp Nephrol 112 e59 e69 10.1159/000213896 1:CAS:528:DC%2BD1MXmsFaltbo%3D 19390220
9. H Tanaka K Tsugawa E Oki K Suzuki E Ito 2008 Mizoribine intermittent pulse therapy for induction therapy for systemic lupus erythematosus in children: an open label pilot study with five newly diagnosed patients Clin Rheumatol 27 85 89 10.1007/s10067-007-0635-9 17483980
10. HA Austin LR Muenz KM Joyce TT Antonnovych JE Balow 1984 Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome Kidney Int 25 689 695 10.1038/ki.1984.75 6482173
11. M Mosca W Bencivelli C Vitali P Carrai R Neri S Bombardieri 2000 The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus Lupus 9 445 450 10.1191/096120300678828640 1:STN:280:DC%2BD3M%2FovVegtg%3D%3D 10981649
12. S Takahashi H Wakui JA Gustafsson J Zilliacus H Itoh 2000 Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein Biochem Biophys Res Commun 274 87 92 10.1006/bbrc.2000.3104 1:CAS:528: DC%2BD3cXkvFarsbc%3D 10903900
13. H Itoh A Komatsuda H Wakui AB Miura Y Tashima 1999 Mammalian HSP60 is a major target for an immunosuppressant mizoribine J Biol Chem 274 35147 35151 10.1074/jbc.274.49.35147 1:CAS:528:DyaK1MXnvFyrtbg%3D 10574997
14. Y Kawasaki K Suyama H Go T Imamura Y Ushijima N Sakai K Hashimoto M Hosoya 2009 Accumulation of macrophages expressing myeloid-related protein 8 associated with the progression of sclerotic changes in children with IgA nephropathy Tohoku J Exp Med 218 49 55 10.1620/tjem.218.49 1:CAS:528: DC%2BD1MXms1WgsLo%3D 19398873